Antiresorptive Agents and Anti-Angiogenesis Drugs in the Development of Osteonecrosis of the Jaw
Medication-related osteonecrosis of the jaw (MRONJ) is a condition of exposed bone in the maxillofacial region, which occurs among subjects treated with antiresorptive agents or anti-angiogenesis drugs, despite the lack of a history of head or neck radiation treatment. Although there are still many...
Saved in:
| Published in | The Tohoku Journal of Experimental Medicine Vol. 248; no. 1; pp. 27 - 29 |
|---|---|
| Main Authors | , , , |
| Format | Journal Article |
| Language | English |
| Published |
Japan
Tohoku University Medical Press
2019
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 0040-8727 1349-3329 1349-3329 |
| DOI | 10.1620/tjem.248.27 |
Cover
| Abstract | Medication-related osteonecrosis of the jaw (MRONJ) is a condition of exposed bone in the maxillofacial region, which occurs among subjects treated with antiresorptive agents or anti-angiogenesis drugs, despite the lack of a history of head or neck radiation treatment. Although there are still many points to be clarified about the mechanism of MRONJ, it is possible to hypothesize a common pathogenetic mechanism for two different classes of drugs: antiresorptive and anti-angiogenetic drugs. These drugs can inhibit angiogenesis by interfering with endothelial cell proliferation and survival, leading to loss of blood vessels and avascular necrosis. This hypothesis could be of immediate translational interest. Targeting the anti-angiogenetic effect of the antiresorptive agents could provide a new possibility for the prevention of treatment of MRONJ. |
|---|---|
| AbstractList | Medication-related osteonecrosis of the jaw (MRONJ) is a condition of exposed bone in the maxillofacial region, which occurs among subjects treated with antiresorptive agents or anti-angiogenesis drugs, despite the lack of a history of head or neck radiation treatment. Although there are still many points to be clarified about the mechanism of MRONJ, it is possible to hypothesize a common pathogenetic mechanism for two different classes of drugs: antiresorptive and anti-angiogenetic drugs. These drugs can inhibit angiogenesis by interfering with endothelial cell proliferation and survival, leading to loss of blood vessels and avascular necrosis. This hypothesis could be of immediate translational interest. Targeting the anti-angiogenetic effect of the antiresorptive agents could provide a new possibility for the prevention of treatment of MRONJ. Medication-related osteonecrosis of the jaw (MRONJ) is a condition of exposed bone in the maxillofacial region, which occurs among subjects treated with antiresorptive agents or anti-angiogenesis drugs, despite the lack of a history of head or neck radiation treatment. Although there are still many points to be clarified about the mechanism of MRONJ, it is possible to hypothesize a common pathogenetic mechanism for two different classes of drugs: antiresorptive and anti-angiogenetic drugs. These drugs can inhibit angiogenesis by interfering with endothelial cell proliferation and survival, leading to loss of blood vessels and avascular necrosis. This hypothesis could be of immediate translational interest. Targeting the anti-angiogenetic effect of the antiresorptive agents could provide a new possibility for the prevention of treatment of MRONJ.Medication-related osteonecrosis of the jaw (MRONJ) is a condition of exposed bone in the maxillofacial region, which occurs among subjects treated with antiresorptive agents or anti-angiogenesis drugs, despite the lack of a history of head or neck radiation treatment. Although there are still many points to be clarified about the mechanism of MRONJ, it is possible to hypothesize a common pathogenetic mechanism for two different classes of drugs: antiresorptive and anti-angiogenetic drugs. These drugs can inhibit angiogenesis by interfering with endothelial cell proliferation and survival, leading to loss of blood vessels and avascular necrosis. This hypothesis could be of immediate translational interest. Targeting the anti-angiogenetic effect of the antiresorptive agents could provide a new possibility for the prevention of treatment of MRONJ. |
| Author | Innao, Vanessa Allegra, Alessandro Pulvirenti, Nicolina Musolino, Caterina |
| Author_xml | – sequence: 1 fullname: Allegra, Alessandro organization: Division of Hematology, Department of Human Pathology in Adulthood and Childhood “Gaetano Barresi”, University of Messina – sequence: 1 fullname: Pulvirenti, Nicolina organization: Division of Hematology, Department of Human Pathology in Adulthood and Childhood “Gaetano Barresi”, University of Messina – sequence: 1 fullname: Innao, Vanessa organization: Division of Hematology, Department of Human Pathology in Adulthood and Childhood “Gaetano Barresi”, University of Messina – sequence: 1 fullname: Musolino, Caterina organization: Division of Hematology, Department of Human Pathology in Adulthood and Childhood “Gaetano Barresi”, University of Messina |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/31080196$$D View this record in MEDLINE/PubMed |
| BookMark | eNpt0E1rGzEQBmBRUhon7an3oGOhrKuP3dXuqRg7XyWQS3JWZWnWltmVXEl26L-PFtsJlJ4EM88MmvcCnTnvAKGvlExpzciPtIFhyspmysQHNKG8bAvOWXuGJoSUpGgEE-foIsYNIbwkov6EzjklDaFtPUG_Zy7ZANGHbbJ7wLMVuBSxcgaPnWLmVtbnGkQb8SLsVhFbh9Ma8AL20PvtkD32HX6MCfK_dPCjzIXR_FIvn9HHTvURvhzfS_R8c_00vyseHm_v57OHQleCp6JTVV1BK6iBzqi2rFgFlLOm07QEvjSaVMy0hHNBzJIbA5UyNVDFtSBKsIZfom-Hvdvg_-wgJjnYqKHvlQO_i5Ixng-u66bM9OpId8sBjNwGO6jwV55SyYAewHhNDNBJbZNK1rsUlO0lJXJMXo7Jy5y8ZCLPfP9n5rT2__rnQW9iUit4syokq3t4t_Q48dbRaxUkOP4K8R2c8g |
| CitedBy_id | crossref_primary_10_1016_j_heliyon_2023_e19468 crossref_primary_10_1016_j_bone_2021_116144 crossref_primary_10_1155_2020_9879876 crossref_primary_10_4103_jispcd_JISPCD_110_22 crossref_primary_10_1007_s10006_024_01214_5 crossref_primary_10_1111_jgs_18414 crossref_primary_10_1111_ors_12578 crossref_primary_10_2485_jhtb_30_323 crossref_primary_10_1016_j_jbo_2024_100650 crossref_primary_10_1007_s00784_023_05359_7 crossref_primary_10_2174_1874210602115010769 crossref_primary_10_1038_s41415_023_5852_3 crossref_primary_10_3390_ijms22094922 crossref_primary_10_1093_jscr_rjad270 crossref_primary_10_1002_dvg_23500 crossref_primary_10_3390_app11083365 crossref_primary_10_3389_fendo_2022_1054827 crossref_primary_10_3390_ijms20194925 |
| Cites_doi | 10.1159/000313787 10.1016/j.cyto.2008.05.010 10.1080/10428190701509806 10.1007/s00520-018-4501-x 10.1007/s00277-018-3296-7 |
| ContentType | Journal Article |
| Copyright | 2019 Tohoku University Medical Press |
| Copyright_xml | – notice: 2019 Tohoku University Medical Press |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1620/tjem.248.27 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1349-3329 |
| EndPage | 29 |
| ExternalDocumentID | 31080196 10_1620_tjem_248_27 article_tjem_248_1_248_27_article_char_en |
| Genre | Journal Article |
| GroupedDBID | --- -~X .55 .GJ 123 29Q 2WC 36B 3O- 53G 5RE 7.U ABCQX ACGFO ADBBV AEGXH AENEX AIAGR ALMA_UNASSIGNED_HOLDINGS BAWUL CS3 DIK DU5 E3Z EBD EMB EMOBN F5P GX1 JSF JSH KQ8 L7B MK0 OK1 OVT P2P RJT RNS RZJ SV3 TKC TR2 W2D WH7 X7J X7M XSB ZGI ZXP AAYXX CITATION CGR CUY CVF ECM EIF M~E NPM 7X8 |
| ID | FETCH-LOGICAL-c573t-fa565e971defda94525e1328fc14e3bdc052d903370db3dde5ad6e1a3c70a7283 |
| ISSN | 0040-8727 1349-3329 |
| IngestDate | Thu Jul 10 23:40:16 EDT 2025 Thu Jan 02 22:59:25 EST 2025 Thu Apr 24 22:55:48 EDT 2025 Tue Jul 01 01:28:58 EDT 2025 Wed Sep 03 06:05:47 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | medications-related osteonecrosis of the jaw antiresorptive agent bisphosphonates anti-angiogenesis agents denosumab |
| Language | English |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c573t-fa565e971defda94525e1328fc14e3bdc052d903370db3dde5ad6e1a3c70a7283 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | https://www.jstage.jst.go.jp/article/tjem/248/1/248_27/_article/-char/en |
| PMID | 31080196 |
| PQID | 2231966684 |
| PQPubID | 23479 |
| PageCount | 3 |
| ParticipantIDs | proquest_miscellaneous_2231966684 pubmed_primary_31080196 crossref_citationtrail_10_1620_tjem_248_27 crossref_primary_10_1620_tjem_248_27 jstage_primary_article_tjem_248_1_248_27_article_char_en |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2019-00-00 |
| PublicationDateYYYYMMDD | 2019-01-01 |
| PublicationDate_xml | – year: 2019 text: 2019-00-00 |
| PublicationDecade | 2010 |
| PublicationPlace | Japan |
| PublicationPlace_xml | – name: Japan |
| PublicationTitle | The Tohoku Journal of Experimental Medicine |
| PublicationTitleAlternate | Tohoku J. Exp. Med. |
| PublicationYear | 2019 |
| Publisher | Tohoku University Medical Press |
| Publisher_xml | – name: Tohoku University Medical Press |
| References | Ruggiero, S.L., Dodson, T.B., Fantasia, J., Goodday, R., Aghaloo, T., Mehrotra, B., O’Ryan, F.; American Association of Oral and Maxillofacial Surgeons (2014) American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw: 2014 update. J. Oral Maxillofac. Surg., 72, 1938-1956. Khan, A.A., Morrison, A., Hanley, D.A., Felsenberg, D., McCauley, L.K., O’Ryan, F., Reid, I.R., Ruggiero, S.L., Taguchi, A., Tetradis, S., Watts, N.B., Brandi, M.L., Peters, E., Guise, T., Eastell, R., et al. (2015) Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J. Bone Miner. Res., 30, 3-23. Ge, Y.L., Zhang, X., Zhang, J.Y., Hou, L. & Tian, R.H. (2009) The mechanisms on apoptosis by inhibiting VEGF expression in human breast cancer cells. Int. Immunopharmacol., 9, 389-395. Alonci, A., Allegra, A., Bellomo, G., Quartarone, E., Oteri, G., Nastro, E., Cicciu, D., De Ponte, F.S. & Musolino, C. (2007) Patients with bisphosphonate-associated osteonecrosis of the jaw have unmodified levels of soluble vascular endothelial growth factor receptor 1. Leuk. Lymphoma, 48, 1852-1854. Allegra, A., Innao, V., Allegra, A.G., Ettari, R., Pugliese, M., Pulvirenti, N. & Musolino, C. (2019) Role of the microbiota in hematologic malignancies. Neth. J. Med., 77, 67-80. Nicolatou-Galitis, O., Kouri, M., Papadopoulou, E., Vardas, E., Galiti, D., Epstein, J.B., Elad, S., Campisi, G., Tsoukalas, N., Bektas-Kayhan, K., Tan, W., Body, J.J., Migliorati, C. & Lalla, R.V.; MASCC Bone Study Group (2019) Osteonecrosis of the jaw related to non-antiresorptive medications: a systematic review. Support. Care Cancer, 27, 383-394. Girolami, I., Mancini, I., Simoni, A., Baldi, G.G., Simi, L., Campanacci, D., Beltrami, G., Scoccianti, G., D’Arienzo, A., Capanna, R. & Franchi, A. (2016) Denosumab treated giant cell tumour of bone: a morphological, immunohistochemical and molecular analysis of a series. J. Clin. Pathol., 69, 240-247. Wood, J., Bonjean, K., Ruetz, S., Bellahcene, A., Devy, L., Foidart, J.M., Castronovo, V. & Green, J.R. (2002) Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J. Pharmacol. Exp. Ther., 302, 1055-1061. Egloff-Juras, C., Gallois, A., Salleron, J., Massard, V., Dolivet, G., Guillet, J. & Phulpin, B. (2018) Denosumab-related osteonecrosis of the jaw: a retrospective study. J. Oral Pathol. Med., 47, 66-70. Allegra, A., Alonci, A., Penna, G., Granata, A., Nastro Siniscalchi, E., Oteri, G., Loddo, S., Teti, D., Cicciu, D., De Ponte, F.S. & Musolino, C. (2010) Bisphosphonates induce apoptosis of circulating endothelial cells in multiple myeloma patients and in subjects with bisphosphonate-induced osteonecrosis of the jaws. Acta Haematol., 124, 79-85. Oteri, G., Allegra, A., Bellomo, G., Alonci, A., Nastro, E., Penna, G., Catalfamo, L., Cicciu, D., De Ponte, F.S. & Musolino, C. (2008) Reduced serum levels of Interleukin 17 in patients with osteonecrosis of the jaw and in multiple myeloma subjects after bisphosphonates administration. Cytokine, 43, 103-104. Carneiro, A., Falcao, M., Pirraco, A., Milheiro-Oliveira, P., Falcao-Reis, F. & Soares, R. (2009) Comparative effects of bevacizumab, ranibizumab and pegaptanib at intravitreal dose range on endothelial cells. Exp. Eye Res., 88, 522-527. Allegra, A., Oteri, G., Nastro, E., Alonci, A., Bellomo, G., Del Fabro, V., Quartarone, E., Alati, C., De Ponte, F.S., Cicciu, D. & Musolino, C. (2007) Patients with bisphosphonates-associated osteonecrosis of the jaw have reduced circulating endothelial cells. Hematol. Oncol., 25, 164-169. Musolino, C., Oteri, G., Allegra, A., Mania, M., D’Ascola, A., Avenoso, A., Innao, V., Allegra, A.G. & Campo, S. (2018) Altered microRNA expression profile in the peripheral lymphoid compartment of multiple myeloma patients with bisphosphonate-induced osteonecrosis of the jaw. Ann. Hematol., 97, 1259-1269. Shibahara, T. (2019) Antiresorptive Agent-Related Osteonecrosis of the Jaw (ARONJ): a twist of fate in the bone. Tohoku J. Exp. Med., 247, 75-86. 11 12 13 14 15 1 2 3 4 5 6 7 8 9 10 |
| References_xml | – reference: Nicolatou-Galitis, O., Kouri, M., Papadopoulou, E., Vardas, E., Galiti, D., Epstein, J.B., Elad, S., Campisi, G., Tsoukalas, N., Bektas-Kayhan, K., Tan, W., Body, J.J., Migliorati, C. & Lalla, R.V.; MASCC Bone Study Group (2019) Osteonecrosis of the jaw related to non-antiresorptive medications: a systematic review. Support. Care Cancer, 27, 383-394. – reference: Girolami, I., Mancini, I., Simoni, A., Baldi, G.G., Simi, L., Campanacci, D., Beltrami, G., Scoccianti, G., D’Arienzo, A., Capanna, R. & Franchi, A. (2016) Denosumab treated giant cell tumour of bone: a morphological, immunohistochemical and molecular analysis of a series. J. Clin. Pathol., 69, 240-247. – reference: Allegra, A., Innao, V., Allegra, A.G., Ettari, R., Pugliese, M., Pulvirenti, N. & Musolino, C. (2019) Role of the microbiota in hematologic malignancies. Neth. J. Med., 77, 67-80. – reference: Ge, Y.L., Zhang, X., Zhang, J.Y., Hou, L. & Tian, R.H. (2009) The mechanisms on apoptosis by inhibiting VEGF expression in human breast cancer cells. Int. Immunopharmacol., 9, 389-395. – reference: Khan, A.A., Morrison, A., Hanley, D.A., Felsenberg, D., McCauley, L.K., O’Ryan, F., Reid, I.R., Ruggiero, S.L., Taguchi, A., Tetradis, S., Watts, N.B., Brandi, M.L., Peters, E., Guise, T., Eastell, R., et al. (2015) Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J. Bone Miner. Res., 30, 3-23. – reference: Oteri, G., Allegra, A., Bellomo, G., Alonci, A., Nastro, E., Penna, G., Catalfamo, L., Cicciu, D., De Ponte, F.S. & Musolino, C. (2008) Reduced serum levels of Interleukin 17 in patients with osteonecrosis of the jaw and in multiple myeloma subjects after bisphosphonates administration. Cytokine, 43, 103-104. – reference: Musolino, C., Oteri, G., Allegra, A., Mania, M., D’Ascola, A., Avenoso, A., Innao, V., Allegra, A.G. & Campo, S. (2018) Altered microRNA expression profile in the peripheral lymphoid compartment of multiple myeloma patients with bisphosphonate-induced osteonecrosis of the jaw. Ann. Hematol., 97, 1259-1269. – reference: Allegra, A., Alonci, A., Penna, G., Granata, A., Nastro Siniscalchi, E., Oteri, G., Loddo, S., Teti, D., Cicciu, D., De Ponte, F.S. & Musolino, C. (2010) Bisphosphonates induce apoptosis of circulating endothelial cells in multiple myeloma patients and in subjects with bisphosphonate-induced osteonecrosis of the jaws. Acta Haematol., 124, 79-85. – reference: Alonci, A., Allegra, A., Bellomo, G., Quartarone, E., Oteri, G., Nastro, E., Cicciu, D., De Ponte, F.S. & Musolino, C. (2007) Patients with bisphosphonate-associated osteonecrosis of the jaw have unmodified levels of soluble vascular endothelial growth factor receptor 1. Leuk. Lymphoma, 48, 1852-1854. – reference: Ruggiero, S.L., Dodson, T.B., Fantasia, J., Goodday, R., Aghaloo, T., Mehrotra, B., O’Ryan, F.; American Association of Oral and Maxillofacial Surgeons (2014) American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw: 2014 update. J. Oral Maxillofac. Surg., 72, 1938-1956. – reference: Carneiro, A., Falcao, M., Pirraco, A., Milheiro-Oliveira, P., Falcao-Reis, F. & Soares, R. (2009) Comparative effects of bevacizumab, ranibizumab and pegaptanib at intravitreal dose range on endothelial cells. Exp. Eye Res., 88, 522-527. – reference: Wood, J., Bonjean, K., Ruetz, S., Bellahcene, A., Devy, L., Foidart, J.M., Castronovo, V. & Green, J.R. (2002) Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J. Pharmacol. Exp. Ther., 302, 1055-1061. – reference: Egloff-Juras, C., Gallois, A., Salleron, J., Massard, V., Dolivet, G., Guillet, J. & Phulpin, B. (2018) Denosumab-related osteonecrosis of the jaw: a retrospective study. J. Oral Pathol. Med., 47, 66-70. – reference: Shibahara, T. (2019) Antiresorptive Agent-Related Osteonecrosis of the Jaw (ARONJ): a twist of fate in the bone. Tohoku J. Exp. Med., 247, 75-86. – reference: Allegra, A., Oteri, G., Nastro, E., Alonci, A., Bellomo, G., Del Fabro, V., Quartarone, E., Alati, C., De Ponte, F.S., Cicciu, D. & Musolino, C. (2007) Patients with bisphosphonates-associated osteonecrosis of the jaw have reduced circulating endothelial cells. Hematol. Oncol., 25, 164-169. – ident: 2 – ident: 3 – ident: 5 – ident: 13 – ident: 14 – ident: 15 – ident: 1 doi: 10.1159/000313787 – ident: 6 – ident: 9 – ident: 12 doi: 10.1016/j.cyto.2008.05.010 – ident: 4 doi: 10.1080/10428190701509806 – ident: 7 – ident: 8 – ident: 11 doi: 10.1007/s00520-018-4501-x – ident: 10 doi: 10.1007/s00277-018-3296-7 |
| SSID | ssj0034076 |
| Score | 2.2940495 |
| Snippet | Medication-related osteonecrosis of the jaw (MRONJ) is a condition of exposed bone in the maxillofacial region, which occurs among subjects treated with... |
| SourceID | proquest pubmed crossref jstage |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 27 |
| SubjectTerms | Angiogenesis Inhibitors - adverse effects anti-angiogenesis agents antiresorptive agent Bisphosphonate-Associated Osteonecrosis of the Jaw - blood Bisphosphonate-Associated Osteonecrosis of the Jaw - etiology bisphosphonates Bone Density Conservation Agents - adverse effects denosumab Endothelial Cells - drug effects Endothelial Cells - metabolism Humans Interleukin-17 - blood medications-related osteonecrosis of the jaw |
| Title | Antiresorptive Agents and Anti-Angiogenesis Drugs in the Development of Osteonecrosis of the Jaw |
| URI | https://www.jstage.jst.go.jp/article/tjem/248/1/248_27/_article/-char/en https://www.ncbi.nlm.nih.gov/pubmed/31080196 https://www.proquest.com/docview/2231966684 |
| Volume | 248 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| ispartofPNX | The Tohoku Journal of Experimental Medicine, 2019, Vol.248(1), pp.27-29 |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lj9MwELbKghAXxJvyUpD2xColid24OVawsFpp4dJFvYXEj9JSklWTcOAf8q-YcZzUpYu07CWqkmmd5vsyM7a_sQk5jKjWgZLC53k-9pkOEj_XSvsB04JPBNPU7NZw9ik-OWen8_F8MPjtqJaaOh-JX5fWlVwHVTgHuGKV7H8g2_8onIDPgC8cAWE4XgnjaVGDx6rKzYURAE0XplwNh8Lxij8tFstygc5sWR293zSLqlM1OlIhzBY_A9RloTBitsuToM2pHd5ebfk0K7-V35sjJ4k9djcIOPtrnn66Nnta2DqaqspwcYTeFzfrn0tcGmrZE9Lu5G2YWhSZGcT9kqEvzra8qNCutMWLWLuYuQMXjmO0N-soT7pJKVd2Ytw1C8Bdt4sHjFTroSlLfErtMIl14RGb7HHVOmTuhPb2S3tBI45QZVmv1I9RhHI_vo2NvWLRYpyiVQpWaWiOEU-7K1glB6S8QW5GnIeoLv0479VGFPrNcSfgxH9kS0Wh6bdOwzvJ0a0V9A8W6t9dH5MCze6RuxZ2b9reyn0yUMUDcrtD_SH5ustHr-WjB7B7e3z0DB-9ZeEB1zyHj16pvR0-4gm0AT4-IucfjmfvTny7g4cvxpzWvs6gv6ASHkqlZZbgHLoKaTTRImSK5lIE40gmAaU8kDmFSDvOZKzCjAoeZBwy38fkoID2nhIvi3IJ6bFMQi2YhEgU5CGnQksmJUaWIXnTPbpU2OXtcZeVdYrdXHjOW-giPiSHvfFFu6rL5WaTFoPe6Mo0GJLXHWopOGychYP3pWyqFPJxiHpxPGFD8qSFs_95iopfuPrs-g0_J3fwZWtHCV-Qg3rTqJeQN9f5K8PIPwiF0hM |
| linkProvider | Geneva Foundation for Medical Education and Research |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Antiresorptive+Agents+and+Anti-Angiogenesis+Drugs+in+the+Development+of+Osteonecrosis+of+the+Jaw&rft.jtitle=The+Tohoku+Journal+of+Experimental+Medicine&rft.au=Allegra%2C+Alessandro&rft.au=Pulvirenti%2C+Nicolina&rft.au=Innao%2C+Vanessa&rft.au=Musolino%2C+Caterina&rft.date=2019&rft.pub=Tohoku+University+Medical+Press&rft.issn=0040-8727&rft.eissn=1349-3329&rft.volume=248&rft.issue=1&rft.spage=27&rft.epage=29&rft_id=info:doi/10.1620%2Ftjem.248.27&rft.externalDocID=article_tjem_248_1_248_27_article_char_en |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0040-8727&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0040-8727&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0040-8727&client=summon |